Advertisement
News
Subscribe to MDT Magazine News

Curemark Announces Four New Sites Participating in Autism Study

December 2, 2010 8:34 am | by Bio-Medicine.Org | Comments

RYE, N.Y., Dec. 2, 2010 /- Curemark, LLC , ( www.curemark.com ), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism...

TOPICS:

OrbusNeich's Genousâ„¢ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents

December 2, 2010 8:33 am | by Bio-Medicine.Org | Comments

HONG KONG, Dec. 2, 2010 /- OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis . The cumulative rate of the study's primary...

TOPICS:

Omnicare could raise $560M from senior note sale

December 2, 2010 7:46 am | by The Associated Press | Comments

Omnicare Inc. said Thursday it is hoping to raise as much as $560 million by selling up to $575 million in convertible senior notes due in 2025.The seller of prescription drugs to nursing homes and long-term care facilities said it priced an offering of $500 million in senior notes, which could...

Advertisement

PlasmaButton therapy offers less invasive treatment for benign prostatic hyperplasia

December 2, 2010 7:40 am | by EurekAlert | Comments

(GolinHarris NY) Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announced today that its revolutionary PlasmaButton vaporization technology can now be used with the Gyrus ACMI...

TOPICS:

The race against age

December 2, 2010 7:40 am | by EurekAlert | Comments

(Deutsches Aerzteblatt International) Impairments to health and physical performance are not primarily a result of aging but of unfavorable lifestyle habits and lack of exercise. This is the position taken by Dieter Leyk and his coauthors in the new issue of Deutsches Arzteblatt...

TOPICS:

New Report Indicates VERILASTâ„¢ Technology From Smith & Nephew Orthopaedics has Lowest Revision Rate Among all Hip Replacement Materials

December 2, 2010 7:38 am | by Bio-Medicine.Org | Comments

MEMPHIS, Tenn., Dec. 2, 2010 /- A newly released patient registry reports that hip replacement implants made from ceramicized metal heads which articulate against polyethylene lined cups have been shown to have superior survivorship compared to implants made from any other material five...

TOPICS:

FDA Clears GeNO LLC's Investigational New Drug Application for Clinical Trials With Its NITROSYLâ„¢ Inhaled Nitric Oxide System

December 2, 2010 7:35 am | by Bio-Medicine.Org | Comments

COCOA, Fla., Dec. 2, 2010 /- GeNO LLC ( www.genollc.com ), a privately held, advanced development-stage technology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a clinical trial with the GeNO...

TOPICS:

Dawson James Initiates Research Coverage of Advanced Life Sciences

December 2, 2010 7:35 am | by Bio-Medicine.Org | Comments

CHICAGO, Dec. 2, 2010 /- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that...

TOPICS:
Advertisement

The Citizen CPR Foundation Launches National Call to Action to Empower Citizens to Save Lives of Those with Sudden Cardiac Arrest

December 2, 2010 7:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 2, 2010 /PRNewswire-USNewswire/ -- The Citizen CPR Foundation (CCPRF) with prestigious co-sponsor organizations and community members have a mission to save lives and treat sudden cardiac arrest by encouraging citizen and community action in 2011 and beyond. The non-profit...

TOPICS:

For cutting CT dose, start with the scout scan

December 2, 2010 7:35 am | by Diagnostic Imaging | Comments

CT scout or scanogram images make up only about 4% of the typical chest/abdominal scan radiation dose, but are an easy target for dose reductions, according to a study presented Wednesday. Further, as technology changes and protocol updates reduce overall dose rates, scout images will...

TOPICS:

NewCardio's Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow

December 2, 2010 7:35 am | by Bio-Medicine.Org | Comments

SANTA CLARA, Calif., Dec. 2, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, announced today that Dr. Dorin Panescu, Chief Technical Officer and Vice President Research and Development, has been named an IEEE Fellow, effective January...

TOPICS:

Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP

December 2, 2010 7:34 am | by Bio-Medicine.Org | Comments

SCHAUMBURG, Ill., Dec. 2, 2010 /- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA's approval of four presentations of midazolam injection, USP, a general anesthetic.  Sagent expects to launch midazolam, which will be offered...

TOPICS:

Sequenom prices stock offering worth $84 million

December 2, 2010 6:45 am | by The Associated Press | Comments

Biotechnology company Sequenom Inc. said Thursday it is publicly offering $84 million in common stock and will use proceeds for general corporate purposes, including research and development.The company is offering 14 million shares at $6 apiece, an 11.9 percent discount to its closing price of...

Remarks: MassMEDIC FDA Update Conference, December 1, 2010

December 2, 2010 6:36 am | by U.S. Food & Drug Administration | Comments

In August 2010, CDRH released for public comment the preliminary reports from the 510(k) Working Group and the Task Force on the Utilization of Science in Regulatory Decision Making. These committees were established in September 2009 to address ...

Sage Science raises $2M financing

December 2, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Sage Science Inc., a developer of laboratory and research-related technologies, has taken in $2.02 million in an equity offering, with an expected total offering of $2.12 million, according to a regulatory filing.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading